Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Tislelizumab is now approved in nine indications in China
Subscribe To Our Newsletter & Stay Updated